Octreotide controlled release - Camurus/Novartis

Drug Profile

Octreotide controlled release - Camurus/Novartis

Alternative Names: CAM-2029; Octreotide chloride controlled release; Octreotide sc depot

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Camurus
  • Developer Camurus; Novartis
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acromegaly; Neuroendocrine tumours

Most Recent Events

  • 29 Jan 2018 Octreotide controlled release is still at phase II for Acromegaly and Neuroendocrine tumours in France, Germany, Italy and Sweden (SC) (Camurus pipeline, January 2018)
  • 01 Apr 2017 Pharmacokinetics and adverse events data from a phase II trial in Acromegaly and Neuroendocrine tumours presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 14 Jul 2016 Novartis and Camurus plan phase III trials for Acromegaly and Neuroendocrine tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top